Table 8 Outcome for biological markers: blood products
From: The clinical use of biomarkers as prognostic factors in Ewing sarcoma
Author | Year | Biomarker | Pt number | P |
|---|---|---|---|---|
Holzer et al, Med Pediatr Oncol 36 (6), 601-4[67] | 2001 | VEGF | 6 | NS |
Pavlakovic et al, Int J Cancer 92, 756-60 [68] | 2001 | VEGF | 4 | 0.017 |
Rutkowski et al, J Surg Oncol 84, 151-9[27] | 2003 | VEGF | 13 | NS |
Fuchs et al, Clin Cancer Res 10, 1344-53[45] | 2004 | VEGF | 31 | 0.0047 |
Jimeno et al, Pediatr Blood Cancer 49, 352-7[69] | 2007 | VEGF | 16 | NS |
Kreuter et al, Eur J Cancer 42, 1904-11[47] | 2006 | VEGF-A | 40 | 0.013 |
Kreuter et al, Eur J Cancer 42, 1904-11[47] | 2006 | VEGFR-1 | 40 | 0.946 |
Kreuter et al, Eur J Cancer 42, 1904-11[47] | 2006 | VEGFR-2 | 40 | 0.946 |
Aparicio et al, Oncology 55, 20-6[9] | 1998 | Lymphocyte count | 116 | 0.0044 |
De Angulo et al, J Pediatr Hematol Oncol 29 (1), 48-52[17] | 2007 | Lymphocyte count | 24 | 0.001 |
De Angulo et al, J Pediatr Hematol Oncol 29 (1), 48-52 [17] | 2007 | Platelet count | 24 | NS |
De Angulo et al, J Pediatr Hematol Oncol 29 (1), 48-52[17] | 2007 | Neutrophil count | 24 | NS |
Aparicio et al, Oncology 55, 20-6[9] | 1998 | Erythrocyte sedimentation rate | 116 | 0.02 |
Oberlin et al, B J Cancer 85 (11), 1646-54[26] | 2001 | Erythrocyte sedimentation rate | 141 | 0.04 |
Yabe et al, Oncol Rep 19 (1), 129-34[70] | 2008 | Erythrocyte sedimentation rate | 20 | NS |